{'fraction_non_alphanumeric': 0.029288702928870293, 'fraction_numerical': 0.0041841004184100415, 'mean_word_length': 5.410714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Choice of anti-helicobacter treatment of gastroduodenal ulcer associated with helicobater pylori].

AIM
Choice of optimal antihelicobacter (AH) treatment of ulcer.


MATERIALS AND METHODS
249 outpatients with duodenal ulcer associated with Helicobacter pylori entered a blind multicenter controlled trial. The patients were given one of the following drugs: metronidazole, tonidazol, amoxicilline, clarithromycin, rovamycin, omeprazole, azitromycin.


RESULTS
Of all the drugs used, rovamycin appeared preferable as it has high AH activity, is safe and cost-effective.


CONCLUSION
Rovamycin has a high AH activity and can be applied for treatment of diseases associated with Helicobacter pylori as a drug of choice.